In today’s episode, Ken and Dawn interview their colleague Dr. Peter Neuhaus, a senior research scientist here at IHMC. Peter is an engineer well-known for his work on wearable robotic devices. In particular, Peter has focused on lower extremity exoskeleton devices and their applications for mobility assistance for paraplegics and other people with disabilities or partial paralysis. In 2016, Peter lead an IHMC team that won a silver medal in the international Cybathlon, a competition conducted in Zurich in which people with disabilities used advanced assistive devices, including robotic technologies, to compete against each other. In today’s interview, Peter talks about IHMC’s humanoid robotic efforts as well as his work with NASA designing an exercise machine for a human mission to Mars or other missions beyond low earth orbit. Peter also describes the work he is doing with IHMC High-Performance Director Joe Gomes, the former Oakland Raiders strength and conditioning coach. Peter and Joe as well as others at IHMC are designing exercise technologies to extend the resilience of high-performing humans, such as astronauts and elite warfighters. Many of these technologies will eventually be able to be utilized by the general public. Links:  Peter Neuhaus IHMC page: https://www.ihmc.us/groups/pneuhaus/  DARPA Robotics Challenge videos: http://robots.ihmc.us/drc/  Cybathlon videos: http://robots.ihmc.us/cybathlon/  IEEE Robotics and Automation Magazine article about Cybathlon: https://arxiv.org/pdf/1702.08656.pdf  IHMC newsletter article about Cybathlon: https://www.ihmc.us/wp-content/uploads/2015/08/IHMCNewslettervol10iss3.pdf  IHMC newsletter article about DARPA Robotics Challenge: https://www.ihmc.us/wp-content/uploads/2017/07/IHMCnewslettervol13iss1.pdf  Show notes: 3:03: Dawn asks Peter about growing up in New York City. 3:33: Ken mentions that after high-school, Peter enrolled at MIT. Ken asks Peter what led him there. 4:04: Ken asks why Peter decided to major in mechanical engineering. 4:35: Dawn asks Peter what led him to travel across the country to attend the University of California, Berkeley for graduate school after he graduated from MIT. 5:10: Dawn asks what it was like for Peter to teach science to 5th– and 6th-graders as well as high-schoolers in Brooklyn after he received his master’s degree from Berkeley. 6:23: Peter talks about how after two years of teaching, he decided his window of opportunity to get a doctorate was shrinking and that it was essentially “now or never,” which led him back to Berkeley. 7:02: Dawn mentions that once Peter finished his doctorate, he went to work for a startup as a mechanical engineer. She asks what sort of work he did there. 7:47: Dawn talks about how a year and a half after getting his doctorate Peter met his future wife, who eventually led him to Pensacola, and in a roundabout way, to IHMC. She asks if he could share how that all came about. 9:22: Ken comments on how since joining IHMC in 2003, Peter has focused on wearable robotics systems and legged robots. Ken further mentions that Peter was one of the lead IHMC researchers participating in the DARPA Learning Locomotion project, where he helped develop quadrupedal locomotion algorithms for the Little Dog robot. Ken asks if Peter could talk about his work on this project? 11:08: Dawn, continuing with the discussion about DARPA projects, mentions that Peter played an important role in both the development of technology and in the management of IHMC’s humanoid robotics effort for the DARPA Robotics Challenge that was held between 2013 and 2015. IHMC placed second and brought home $1 million in prize money. Dawn asks what that experience was like. 12:10: Ken mentions there were three competitions that were part of the robotics challenge, and asks Peter to talk about IHMC’s performance in each of the competitions. 12:57: Dawn mentions that for more than a decade, Peter has been working on exoskeletons, wearable robotic devices that assist people with paralysis and other disabilities. She asks Peter how he got interested in this, and if he could give an overview of what is involved in the development of exoskeletons. 14:39: Ken comments on how wearables are a challenging application for robotics. He asks if Peter could elaborate on some of the specific technical challenges that go along with it. 15:27: Dawn changes the topic to the Cybathlon, a competition, held in Zurich, Switzerland for people with disabilities who are supported by modern assistive technology. IHMC won another silver medal in that competition and Dawn asks about the IHMC team’s preparation for the Cybathlon. 18:18: Ken mentions that a key factor that set IHMC’s exoskeleton apart from the rest at the Cybathlon was the incorporation of powered ankles, which improved mobility. Ken asks Peter to talk about the importance of this feature that the team added to the exoskeleton. 20:05: Dawn asks whether the balancing algorithms that are used in humanoid robots could also be used for ekoskeletons. 22:25: Dawn reads something that Peter once said: “Humans are great at perception. We can look around an area and see where we should go, and what we should step on. But communicating that information to a computer is pretty challenging.” Dawn asks Peter what those challenges are, and if he could speculate about the features that might be incorporated into a state-of-the-art exoskeleton 10 years from now. 24:41: Dawn asks about Peter’s involvement in the X1 exoskeleton that was developed in collaboration with NASA Johnson Space Center. 25:32: Continuing the discussion about NASA, Ken mentions that Peter and his team are also working with NASA on an exercise machine for long duration deep-space missions, such as a Mars mission. Ken talks about how astronauts are so susceptible to bone density and muscle loss while in space that exercise is very important. He asks Peter about the challenges of building exercise devices specifically designed for microgravity. 27:22: Dawn quotes the director of exercise physiology of the Johnson Space Center, Dan Hagen, who said, “Exercise is the number one health priority for astronauts when they are in space. No other activity, except eating and sleeping, is given that much priority. Two and a half hours each day are devoted to fitness.” Dawn asks if a computerized exercise machine could reduce the amount of time someone needs to train, which would free them up to be more productive. 28:33: Ken asks about Peter’s thoughts on how his work with NASA on exercise technology could have applications here on earth. 29:21: Dawn mentions that IHMC recently hired Joe Gomes as the institute’s high-performance director. She goes on to mention that Ken is in the process of building a team to search for ways to extend the resilience of high-performing humans operating in extreme environments and conditions. The team multi-disciplinary team is comprised of engineers and software developers, physicians, pathologists, social scientists, and human-performance specialists to improve training and maximize a person’s physical and cognitive performance. In light of that, Dawns asks Peter to give an overview of how he is teaming up Joe to develop an exercise machine. 30:18: Dawn comments on how health and fitness wearables and apps have, up to this point, merely tracked activity and reported it after the fact. She goes on to ask if it’s correct that the device Peter and his team are developing will enable both the trainee and trainer to receive immediate feedback and prompts during a workout. 31:14: Ken asks Peter whether the technology he is developing with Joe and the rest of the team will get away from a one-size-fits-all model and lead to a more personalized-training model. 32:26: Dawn asks Peter about rehabilitation, and if the exercise machine, or some version of it, will help track and quantify someone’s rehab from injury. 33:37: Dawn asks about the potential commercial uses for the exercise device. 34:21: Dawn asks if computer-controlled motorized resistance also makes exercise safer. 34:55: Ken asks Peter to discuss how the exercise device could potentially help the aging population given that muscle mass begins to decrease substantially after age 60 and leads to falls, frailty and insulin resistance, among much else. 36:49: Dawn asks Peter about the Mobility Unlimited Challenge, sponsored by the Toyota Mobility Foundation. She asks about IHMC’s role and why Toyota is interested in exoskeleton technology. 37:34: Dawn mentions that recently IHMC hosted the 13th annual Dynamic Walking Conference, where students, professors and engineers from around the world gathered in Pensacola for five days of presentations and demonstrations. She asked Peter to explain what the conference was about and what were some of the highlights from the meeting. 38:57: Ken mentions that 2020 is shaping up to be a big year for Peter and the entire IHMC Robotics group. In addition to the Toyota Mobility Challenge, the next Cybathlon is also scheduled for 2020. Ken asks if Peter could discuss his plans for that event. 39:45: Dawn brings up how Peter likes to participate in triathlons, and that he’s been quite active in the triathlon club in Pensacola. She says she understands that Peter recently had to give up running and asks about if that’s true. 41:01: Dawn closes by asking Peter if there is any chance that one day some of the technology Peter is developing could help him get back into running.    

Dr. Brendan Egan is an Associate Professor of Sport and  Exercise Physiology at Dublin City University who is well known for research that shows resistance training can improve strength, muscle mass, reduce falls in older people, and perhaps even extend lifespans. In addition to being a first-class researcher, Brendan is also a stand-out player in Ireland’s national sport, Gaelic football. His current research is exploring the synergy between nutrition and exercise interventions to optimize performance in athletes and the elderly. Current projects also involve protein hydrolysates in recovery and glycemic management; leucine and n-3 PUFAs in the elderly; and exogenous ketones and athletic performance. Links:  Brendan Egan’s faculty page:  https://dcu.academic.ie/live/!W_VALOCAL_DCU_PORTAL.PROFILE?WPBPRSN=1631629 Brendan Egan’s Researchgate profile https://www.researchgate.net/profile/Brendan_Egan2/contributions Brendan Egan’s TEDx talk: https://youtu.be/LkXwfTsqQgQ Exercise Metabolism and the Molecular Regulation of Skeletal Muscle Adaptation https://www.sciencedirect.com/science/article/pii/S1550413112005037 Metabolism of ketone bodies during exercise and training: https://physoc.onlinelibrary.wiley.com/doi/epdf/10.1113/JP273185 Fueling performance: Ketones Enter the Mix: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(16)30438-7 Does Strength-Promoting Exercise Confer Unique Health Benefits? https://academic.oup.com/aje/article-abstract/187/5/1102/4582884?redirectedFrom=fulltext Does Strength-Promoting Exercise Confer Unique Health Benefits? https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/JP275938 Show notes: 2:46: Dawn opens by mentioning that Brendan was born in Detroit, and that his Irish father moved the family to Ireland when Brendan was 3 years old. Dawn asks if Brendan’s mother was American. 4:09: Dawn comments on how Brendan was very athletic as a child and played Gaelic football, which is Ireland’s national sport, and asks if he could explain how this game is played. 6:02: Ken, following up on the last question, asks what Brendan’s training is like for this sport, and how he manages to fit it into his busy schedule as a professor. 7:41: Dawn asks if it is true that even though Brendan’s best grades were in math and physics, he never considered a career in science while he was in high school. 8:37: Dawn mentions that Brendan ended up at the University of Limerick after graduating, asking what made him decide to attend Limerick as well as what prompted him to major in sports and exercise science. 9:46: Dawn asks about two people, Phil Jakeman and John Kirwan, who played a big role in shaping Brendan’s education at Limerick. 11:58: Dawn comments on how after completing his bachelor’s of science degree, Brendan went to work on his master’s, heading to the UK and attending Loughborough University where he graduated with distinction in sports exercise and nutrition. Dawn asks what made him decide to attend Loughborough, and what stood out about his time there. 13:33: Dawn mentions that Brendan returned to Ireland in 2004 to start his doctoral studies under the supervision of Dr. Donal J O’Gorman at Dublin City University. Dawn asks what that experience was like. 15:06: Ken asks what Brendan learned from his research with Dr. O’Gorman, which focused on skeletal muscle adaptation to exercise and, in particular, continuity between acute molecular responses to individual bouts of exercise and the adaptations in skeletal muscle induced by exercise training. 18:30: Dawn asks what took Brendan to Karolinska Institute in Stockholm. 19:51: Brendan talks about his work at Karolinska using animal intravenous cell systems, and his research into transcriptional regulation of skeletal muscle insulin resistance and type 2 diabetes utilizing small non-coding RNA’s. 23:39: Ken mentions that Brendan’s first faculty position was at the University College Dublin in 2011, where he spent five years establishing his own independent research group. He then moved to Dublin City University in 2016. Ken asks how Brendan developed his research group, and what kind of work the group does now. 25:44: Dawn asks Brendan to discuss the prevalence of the age-related loss of muscle function and mass, which often leads to sarcopenia. She also asks about its effects on individuals as well as its impact on society. 27:45: Ken mentions that the heavy use of Prednisone, which a lot of older people are put on for long periods of time, rapidly diminishes their muscle mass. 29:35: Ken mentions that falls are a huge issue, seemingly associated with the loss of fast-twitch muscle as we age, and that falls are more a result of loss of power than loss of strength and mass. He proposes that this is a major, yet overlooked, driver of the prevalence of falling in the older population. 31:11: Ken comments on how there are complex and interacting causes of this loss of mass, strength and power which are not completely understood yet. He lists off certain drivers such as: insulin resistance; decreased availability of anabolic hormones coupled with increased anabolic resistance; the need for more protein as we age; decreased motor neuron function; elevated intercellular oxidative stress; reduction in satellite cell numbers and regenerative capacity; elevated myostatin signaling; reduced physical activity; increased chronic inflammation; changes in autophagy; and mitochondrial abnormalities. Ken asks Brendan to share his thoughts on what he considers the primary drivers of muscle loss. 33:06: Dawn mentions that one of Brendan’s most recent research studies is centered on the optimal way to exercise in terms of time efficiency. She inquires as to what the best combination of exercise would be for someone with a limited amount of time per week. 35:53: Dawn asks Brendan to talk about the importance of leg strength. 37:05: Dawn mentions that it has been well established for many years that resistance training can improve strength and muscle mass, and reduce the incidence of falls and fractures. She asks Brendan to talk about a recent study, done over the course of 15 years with more than 30,000 participants 65 years and older. The study showed that people who did strength training twice a week lowered their risk of dying by almost half. 38:33: Dawn asks what Brendan found in a follow-up study he did where he looked at a nutrition intervention that featured a high protein diet in combination with exercise versus a high protein diet alone. Unlike most similar studies, Brendan’s follow-up study used whole foods rather than protein supplements. 40:47: Dawn mentions that Brendan and other scientists at UCD are currently investigating a dairy-based protein which has been predigested from hydrolysate to see if it will enhance the insulin response and lead to a faster recover compared to other protein and carbohydrate drinks. 42:06: Ken comments on how optimal recovery post-exercise is more and more appreciated, and it’s obviously desired across athletic populations. He asks what happens at the cellular and molecular level during recovery that Brendan finds most relevant and interesting. 43:50: Dawn mentions that Brendan has been looking at exogenous ketone supplementation, particularly in the area of sport science, and how it might relate to athletic performance, and asks what this research is specifically focused on at the moment. 44:41: Ken asks Brendan for his thoughts on increasing the circulating availability of BHB by consumption of exogenous ketones and wonders if it would recapitulate the many positive effects of decreasing carbohydrate intake, which manifests itself in those engaged in a keto-adapted phenotype. 46:20: Dawn mentions that in some circles there is concern that one might overload the mitochondria by providing both high levels of glucose and ketones, asking what Brendan’s thoughts are on this. 47:23: Dawn asks what we know about the impact of exogenous ketones in athletic performance. 51:36: Dawn asks about exogenous ketone esters, particularly the HVMN monoester. She also asks about the AcAc diester developed by Dominic D’Agostino. She supposes that the two different compounds would have distinct pharmacokinetics and somewhat different effects. She asks Brendan to discuss this. 54:39: Dawn mentions that Brendan has given ketone salts and esters to athletes, and that there’s talk in the community about the tolerability of these different compounds. She asks about his experience with them and how he has improved the tolerability in his studies. 56:02: Ken asks about the effects of exogenous ketones on carbohydrate metabolism in high intensity sport, and what he thinks of the glycogen sparing versus glycogen impairing debate around exogenous ketones. 1:00:39: Dawn mentions that exogenous ketones lower blood glucose, asking what the role of the hepatic glucose output is, versus the change in peripheral uptake, and asks Brendan if he thinks BHB could be altering peripheral glucose uptake. 1:02:24: Ken asks about Brendan’s thoughts on studies concluding that exogenous ketone esters helped blood ketone concentrations reach greater than 2 millimolar and is likely a key mediator of any potential ergogenic effect. 1:03:32: Ken mentions the topic of recovery, pointing out that there have been several papers in recent years that look at the BHB monoester and recovery. Ken asks Brendan to discuss these studies and their implications for future research. 1:07:10: Dawn asks if exogenous BHB might have the same effect as exercise, which has long been known to increase brain derived neurotrophic factor (BDNF) which enhances mental abilities, reduces anxiety, and increases neuroplasticity, considering that BDNF has been shown to be inhibited by histone deacetylases (HDACs), and that BHB inhibits HDACs. 1:08:21: Ken mentions that there have been a few ingestibles that have had effects that act as exercise mimetics. He inquires as to Brendan’s thoughts on these compounds. 1:10:14: Dawn asks Brendan about how Ireland is projected to become the fattest nation in Europe in the next 10 to 15 years. 1:11:07: To wrap things up, Dawn asks Brendan to give three to five pieces of advice for living a longer and healthier life, no matter the age.

Today’s episode features Dr. Valter Longo, director of the Longevity Institute at the University of Southern California. Valter is best known for his research on stem cells and aging as well as his fasting-mimicking diet. Often referred to as FMD, the diet is intended to avoid the downsides of fasting while reaping the health benefits of a calorie-restrictive diet. Over a 25-year career, Valter has published numerous papers about the ways specific diets can activate stem cells and promote regeneration and rejuvenation in multiple organs to reduce the risk for diabetes, cancer, Alzheimer’s and heart disease. He writes about this research and diet in a book that was released earlier this year, “The Longevity Diet: Discover the New Science Behind Stem Cell Activation and Regeneration to Slow Aging, Fight Disease and Optimizer Weight.” The book details an easy-to-follow everyday diet that is combined with short periods of the fasting-mimicking diet. Valter says the diet has the potential to help people live healthier and longer lives. Valter is a native of Genoa, Italy and moved Chicago when he was 16. He received his bachelor’s of science degree at the University of North Texas in 1992 and his Ph.D. at UCLA in 1997. Links: Longevity Center website: http://longevityinstitute.usc.edu Longo’s USC faculty page: http://gero.usc.edu/faculty/longo/ “The Longevity Diet”: https://amzn.to/2s1fcky A periodic diet that mimics fasting promotes multi-system regeneration: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509734/ Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration: https://www.cell.com/cell/fulltext/S0092-8674(17)30130-7 Fasting-mimicking diet and markers/risk factors for aging: http://stm.sciencemag.org/content/9/377/eaai8700 Prolon FMD website: https://prolonfmd.com/fasting-mimicking-diet/?doing_wp_cron=1526216346.5062971115112304687500 Show notes: 2:24: Dawn opens the interview by mentioning that Valter was born and raised in Genoa, Italy, the hometown of Christopher Columbus. She asks if reports of him driving his neighbors mad playing Dire Straits, Jimmy Hendricks and Pink Floyd on his electric guitar as a youth are accurate. 2:43: Dawn asks Valter what his parents said when he tried to talk them into letting him go to London to be a rock star when he was 12 years old? 3:10: Valter left home when he was 16 to go visit an aunt in Chicago, but ended up staying in Chicago to go to school and play music. Dawn asks what that was like? 3:49: Dawn comments on how in addition to being exposed to some of the best blues music in the world, Valter also was exposed to some of the unhealthiest food in the world. Valter then talks about what he refers to as “the heart-attack diet.” 4:48: Dawn asks what lead Valter to attend the University of North Texas College of Music. 5:30: Valter joined the Army Reserve to help pay for college and ended up assigned to a battalion of Army tankers. Ken asks Valter what that was like. 6:15: Dawn asks if it’s true that the idea of directing a marching band lead Valter to switch majors as a sophomore. 7:07: Dawn comments on how not many jazz performance majors, who have never taken a biology course, decide to switch their major to biochemistry. She asks Valter what the people in the biochemistry department had to say about that. 8:04: Dawn mentions that when Valter was five years old, he saw his ailing grandfather pass away. She asks him to talk about that experience and the role it played in his decision to study aging. 9:14: Dawn mentions that after switching over to biochemistry and graduating from college in 1992, Valter headed to UCLA, which at the time was one of the world’s leading centers of longevity research. She asks Valter how that opportunity came about. 10:22: Ken brings up Valter’s work at UCLA in the lab of the pathologist, Roy Walford. Valter studied the effects of caloric restriction in the lab and Ken asks Valter to talk about what he learned. 11:25: Dawn comments that while in Walford’s lab, Valter made two important discoveries using a method that he invented. Dawns asks him to describe the discoveries. 13:20: Dawn asks Valter what led him to do his post-doc work at the University of Southern California, and what the focus of his research was at USC. 14:04: Dawn asks what it was like to study in a community of dwarves in Ecuador, a group of people who lack the receptor for the growth hormone, which is known as Laron syndrome. Valter talks what he learned from that experience. 16:08: Ken notes that these dwarves seem to be nearly immune to cancer and diabetes. Accidents, convulsive disorders and alcohol deaths, however, account for 50 percent of their mortality. Among non-dwarf relatives, these same causes of mortality account for just three percent of deaths. Ken asks Valter what causes this big disparity. 17:54: Dawn recounts that Valter went on to become a professor of gerontology and biological sciences at USC, and that in 2011 he became the director of the Longevity Institute. She goes on to say that the institute is not just interested in the idea of people living longer, but also understanding how people can live healthier longer. She asks if Valter could give some background on the institute and the type of research it does. 19:27: Ken notes that Valter believes it is smarter to intervene on aging itself, rather than try to prevent and treat diseases one by one as they come up. Ken asks Valter to talk about that. 21:04: Dawn mentions that Valter has traveled the world studying people in “blue zones,” areas of the world with the longest-lived populations. She goes on to mention that because of his time with centenarians, Valter concluded that in order to understand how people can live healthy lives, one needs to go beyond the scientific, epidemiological, and clinical studies, and investigate actual populations that age successfully. 23:11: Ken mentions that Valter had the opportunity to know Emma Romano, who lived to 117 and was reportedly the oldest person in the world. He goes on to mention that Emma’s sisters also lived into their 90s and some of the sisters made it to 100. These women, it would seem, were rare individuals who could eat and do just about anything they wanted and still age successfully. Ken asks how much of a role genetics played in their lifespan. 24:30: Dawn shifts gears to talk about Valter’s book “The Longevity Diet,” which is the outgrowth of Valter’s 30 years of research on aging. The book describes a daily nutritional regiment that is combined with the “fasting mimicking diet.” Dawn asks if Valter could define the fasting-mimicking diet. 27:02: Ken asks Valter what it is about the fasting-mimicking diet that actually mimics fasting. 28:38: Dawn asks if one should measure markers such as glucose, ketones, insulin, and IGF-1 while undergoing the fasting mimicking diet. 29:42: Dawn asks if the implementation of the diet requires a doctor’s supervision. 30:46: Dawn inquires as to what a typical fasting-mimicking diet meal looks like. 31:13: Dawn asks how Valter arrived at the 5-day period as the necessary time to experience the benefits of the fasting-mimicking diet. 32:22: Dawn asks if there are populations that Valter wouldn’t recommend the diet to. 33:33: Shifting gears, Ken asks if one can have coffee on the fasting-mimicking diet, mentioning that Valter’s grandfather and Emma Romano likely enjoyed espresso. 35:01: Ken mentions that Valter has said that skipping breakfast increases overall morality and asks him to explain this. 36:42: Dawn mentions that Valter has published a number of papers that indicate that cycles of fasting and refeeding can cause multisystem regeneration and rejuvenation that lead to extended health spans and effects ranging from those on the immune system to the nervous system to muscles. She asks Valter to talk about this. 38:27: Ken asks if Valter could share what he calls the “five pillars of longevity.” 41:31: Dawn asks about the mechanism by which fasting causes an unfavorable environment for cancer cells. 44:24: Ken brings up metformin as an example of a compound that can artificially induce some of the benefits of fasting in the body. 45:45: Ken returns to IGF-1, asking what role it plays in both health and disease. 46:31: Ken brings up the epidemiology research done in the 2011 meta-analysis by Burgers Atoll which showed that both low and high IGF-1 concentrations are associated with increased mortality, essentially showing that the hazard ratio appears U shaped in that both ends of the spectrum are hazardous to a person’s health. Ken asks if there is a sweet spot, or if Valter considers it to be a case of the lower the better, or if it somewhat depends on a person’s age? 48:42: Ken mentions that something that tends to be overlooked in discussing IGF-1 is that fasting, the ketogenic diet, and other such things increase the receptor sensitivity for IGF-1. Thus, even at a relatively low level, the effects would not be the same for someone not in a state of ketosis. 49:52: Dawn asks if protein intake is the only dietary factor involved in regulating IGF-1 levels. 50:21: Ken mentions that Valter’s 2014 cell metabolism paper leveled the risk firmly at the door of IGF-1 concentrations. Ken brings up that IGF-1 regulation of metabolism, however, is more about the interactions of IGF-1 with binding proteins. Ken asks how much IGF binding proteins play a role in IGF. 51:42: Dawn brings up that in 2014 Valter published a study with Levine Addal that said, “We provide convincing evidence that a high-protein diet, particularly if the proteins are derived from animals, is nearly as bad as smoking for your health.” She asks Valter to explain the process of coming to that conclusion. 52:33: Following up on that question, Ken mentions that the risks purported in the paper were relative risks, not absolute risks. In other words, the relative risk of dying from cancer in the high-protein group was roughly four times that of the low-protein group, but the absolute change in risk was maybe half of one percent. Ken points out that depending on how one presents the risk, it could lead to different headlines. 53:26: Ken comments on how he believes the presentation of risk to be misleading, because the change in absolute risk was so negligible as to be noise. 53:58: Ken, returning to protein, mentions that protein intake is complex and multifactorial. Ken asks Valter if the epidemiological research that has been discussed in the interview is able to tease out the important nuances and variables. 56:43: Dawn mentions that Valter often receives emails from people diagnosed with cancer, autoimmune disorders and neurodegenerative diseases who are seeking options beyond the standard treatments offered by their doctors. Valter says this was a key reason he established the Create Cures Foundation, and goes on to give an overview of the foundation and how it is funded. 58:01: Interview ends.

Dr. Keith Baar joins Ken and Dawn today for the second of his two-part interview for STEM-Talk. Keith is a renowned scientist in the emerging field of molecular exercise physiology who has made fundamental discoveries on how muscles grow bigger, stronger, and more fatigue resistant. He is the head of the Functional Molecular Biology Laboratory in the Department of Neurobiology, Physiology, and Behavior at the University of California, Davis. In his lab, he leads a team of researchers attempting to develop ways to improve muscle, tendon and ligament function. Part one of our interview, episode 62, covered Keith’s childhood in Canada and his undergrad years at the University of Michigan as well as his time at the University of California, Berkeley, where he earned a master’s degree in human biophysics. We talked about Keith’s work at the University of Illinois, where he received a doctorate in physiology and biophysics. We also covered Keith’s time in the lab of John Holloszy, who is known as the father of exercise research in the United States, as well as the five years Keith spent at the University of Dundee in Scotland. Episode 63 picks up with Keith explaining his decision to return to the states and join the faculty at the University of California, Davis.  Ken and Dawn then talk to Keith about his most recent research, some of which is looking at how to determine the best way to train, as well as what types of foods compliment training to decrease tendon and ligament injury and accelerate return to play. This work has the potential to improve muscle function not only in athletes, but also improve people’s quality of life as they age. Another key topic covered in part two of our interview is the research Keith is doing on a ketogenic diet and its potential to reduce cancer rates and improve cognition. Keith also provides his thoughts on what optimal workouts and nutrition should look like. Links: Baar’s UC Davis physiology department bio: https://www.ucdmc.ucdavis.edu/physiology/faculty/baar.html Baar’s UC Davis biology department bio: https://biology.ucdavis.edu/people/keith-baar Functional Molecular Biology Lab website: http://www.fmblab.com/  Molecular brakes regulating mTORC1 activation in skeletal muscle paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137116/ Age-related Differences in Dystrophin article: https://www.ncbi.nlm.nih.gov/pubmed/27382038 Show notes: 2:54: Dawn begins part 2 of our interview by mentioning that for the past eight years, Keith has been working at the University of California Davis. She asks Keith what prompted him to return to the U.S. from Scotland and join the faculty at UC Davis. 3:37: Dawn points out that Keith’s Functional Molecular Biology Lab conducts research across a range of related topics, including musculoskeletal development and adaptation as well as methods for engineering functional musculoskeletal tissues in vitro. She asks Keith to give a high-level overview of some of that research. 4:16: Dawn comments that some of Keith’s recent work has shown that we can use specific nutrition and training strategies to optimize injury recovery and prevention. She goes on to say that musculoskeletal injuries are among the most common problems that active people have. 8:45: Ken talks about how Keith has noted that tendon stiffness is dependent upon collagen content, and the amount of crosslinks within. He goes on to mention that Keith has developed various training modalities, as well as nutritional protocols, that can increase and decrease tendon stiffness. Ken begins this line of inquiry by asking about the training methods for this purpose. 12:04: Following up on the previous question, Ken asks whether anyone has looked at how blood flow restriction training, which is increasing in popularity, affects tendon stiffness. 13:32: Dawn moves on to asking about nutrition. She mentions that Keith’s lab has done a great deal of groundbreaking work on the use of gelatin and a small amount of vitamin C to augment collagen synthesis in tendons, ligaments, cartilage, and bone. She asks if he could talk about this nutrition protocol and its effects, particularly when combined with jumping rope. 17:52: Ken mentions that this work is not only interesting scientifically, but it has an immediate, practical application that people can use in their life. Ken goes on to say that those suffering from stress fractures or a variety of other ailments could benefit from this. 21:09: Ken mentions that there are several different forms of collagen, asking if there is any particularly efficacious form, or if they function equally. 22:40: Ken comments that it is not just lower body weakness and injuries in tendons, but also tendonitis that is found in the shoulders and elbows. He asks if there is a variant of Keith’s protocol that is suited for this sort of tendonitis as well. 24:37: Ken asks a question submitted by friends in the special ops community. He mentions that one of their biggest issues is force absorption, due to the repeated, substantial, damage accrued in both training and in operations. He goes on to ask if a focus on eccentric training would lengthen fascicles to allow for greater absorption, and how does it influence the ability to contract concentrically. 26:13: Dawn mentions that she has heard Keith discuss “sugar cross-linking” in the context of aging and diabetes. She asks if this explains why diabetics suffer an increased incidence of tendon and ligament ruptures and injuries. 28:22: Ken, coming back to tendon stiffness, mentions that in addition to fast exercise, inactivity also leads to increased tendon stiffness, counterintuitive as that is. He asks if Keith could discuss this, somewhat surprising, fact. 30:20: Ken comments that ligament engineering is another fascinating area of Keith’s research; he goes on to say that Keith and his colleagues recently engineered the first in vitro ligaments. He goes on to inquire as to how these ligaments are created, what insights can be gleaned from them, and how Keith sees them being used in the future. 34:23: Ken states that mTOR inhibition by rapamycin is arguably the only strategy that has reliably resulted in lifespan extension across a multitude of different species. He goes on to say that we know that mTORC1 activation increases muscle mass and strength, which is critical for optimizing health span into old age. He goes on to bring up a recent paper Keith co-authored with Megan Roberts that showed the ketogenic diet had tissue-specific effects on mTORC1 signaling; decreasing signaling in the liver, while increasing it in the muscle. Ken postulates that perhaps researchers should focus their attention on tissue-specific mTOR activity, to further elucidate the issue of balancing mTOR for longevity with the maintenance of muscle for strength quality. Ken asks Keith if he had unlimited resources, how would Keith design a study to explore this. 43:32: Ken asks if Keith is familiar with a class of drugs that one could characterize as PPAR-delta agonists, sometimes called exercise mimetics, given the overlap between the effects of the ketogenic diet and this class of drugs. 45:10: In regards to longevity, Dawn mentions that few would argue that many elite athletes train for performance at the expense of health. She asks what would be Keith’s overall training recommendation for someone who wants to maximize healthspan and lifespan, and if that is possible while also striving for top levels of performance. 49:24: Ken comments on a belief in the world of “bro science,” that post-exercise carbohydrate ingestion is absolutely necessary for maximizing the anabolic response of resistance training. Ken asks if this is true, and if not, if Keith would educate us as to why and what optimal nutrition and workouts should look like. 51:18: Ken asks what Keith sees as the role of autophagy in the maintenance of muscle mass in aging adults. 53:48: Ken comments on the phenomenon of older people developing anabolic resistance, much like insulin resistance; mentioning a paper that recently looked at the ketogenic diet in that context and found it increased IGF-1 receptor sensitivity. 54:46: Dawn asks to what extent does Keith think a person’s baseline body composition can impact the response to an exercise stimulus. 55:44: Ken points out that Keith has been a scientific advisor for a number of different athletic teams and organizations, pointing out that Keith works to maximize the effects of training for both endurance and strength as well as ways to minimize injury. Ken asks Keith what that experience has been like. 58:27: Ken mentions his intrigue with the mission statement of Keith’s Functional Molecular Biology Lab: “To perform world class musculoskeletal research in a family environment.” Ken asks Keith to explain the story behind including “a family environment” in his mission statement. 1:01:08: Interview ends.

Today’s episode is the first of a two-part interview with Dr. Keith Baar, the head of the Functional Molecular Biology Laboratory in the Department of Neurobiology, Physiology, and Behavior at the University of California, Davis. In his capacity as a researcher, Keith has made fundamental discoveries on how muscle grows bigger, stronger, and more fatigue resistant. He is a renowned scientist in the emerging field of molecular exercise physiology, and is leading a team of researchers attempting to develop ways to improve muscle, tendon and ligament function. Part one of our interview features our conversation with Keith about his background and his time time in the lab of John Holloszy, who is known as the father of exercise research in the United States. Episode 63 of STEM-Talk has Dawn and Ken talking to Keith about his most recent research, which is looking at how to determine the best way to train, as well as what types of foods compliment training to decrease tendon and ligament injury and accelerate return to play. This work has the potential to improve muscle function and people’s quality of life, especially as they age. Ken and Dawn also have a conversation with Keith about the research he is doing on a ketogenic diet and its potential to reduce cancer rates and improve cognition. Links: UC Davis physiology department bio: https://www.ucdmc.ucdavis.edu/physiology/faculty/baar.html UC Davis biology department bio” https://biology.ucdavis.edu/people/keith-baar Functional Molecular Biology Lab website: http://www.fmblab.com Molecular brakes regulating mTORC1 activation in skeletal muscle paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137116/ Age-related Differences in Dystrophin article: https://www.ncbi.nlm.nih.gov/pubmed/27382038  Show notes: 3:14: Dawn opens the interview by mentioning that Keith grew up in Canada, and asks what he was like as a child. 4:02: Dawn asks if Keith was interested in science as a kid. 4:53: Dawn comments that after high school, Keith came to the U.S. to attend the University of Michigan, where he earned a bachelor’s degree in kinesiology. She Keith if Michigan was where he first became interested in the science of how muscles work. 7:54: Dawn asks Keith if he played any sports at Michigan. 8:34: Dawn asks what lead Keith to attend the University of California, Berkeley to pursue a master’s degree in human biophysics. 9:39: Dawn mentions that after his time at Berkeley, Keith returned to the Midwest to attend the University of Illinois where he received his doctorate in physiology and biophysics. She asks why he decided on Illinois for his doctoral work. 11:12: Ken mentions that Keith’s Ph.D. work focused on the effect of resistance exercise on specific molecular markers that are related to muscle growth. He goes on to say that Keith identified that mTOR complex 1 was activated in response to resistance exercise and that the activation was proportional to the load across the muscle. He asks Keith to talk about this work and its significance. 16:20: Ken comments how surprising that discovery must have been. 17:33: Ken asks Keith to explain the two basic ways of activating mTORC1 in skeletal muscle. Ken also asks whether these two are merely additive, or if together they elicit a greater muscle protein response than either would independently. 29:49: Dawn mentions that after Illinois, Keith went to work in the lab of John Holloszy at Washington University in St. Louis, a professor of medicine who is known as the father of exercise research in the United States. Dawn asks if is Holloszy is the one who discovered that when people do endurance exercise that their muscles accumulate more mitochondria. 32:24: Ken asks about the role of PGC-1a. 38:43: Ken comments that we know most sports require a combination of strength and endurance for optimal performance, bringing up the topic of concurrent training. 48:02: Ken asks if we know which form of AMPK is activated by things such as Metformin or the ketogenic diet. 49:24: Dawn comments that Keith eventually accepted a position at Michigan where he worked with Bob Denis, who figured out how to engineer muscles as well as ligaments. She asks Keith to share some things about the research they did together. 50:41: Dawn mentions that after Michigan, Keith accepted a position at the University of Dundee in Scotland, where he worked for 5 years. Dawn asks what that experience was like. 55:20: Ken mentions that from looking at the literature, it seems as though Keith discovered that the non-contractile portion of the muscle plays a key role in the transfer of force, and that this is nearly as important as the size of the muscle fiber itself. He asks Keith to elaborate on this finding. 58:45: Ken asks if Keith’s work has elucidated a potential countermeasure to the loss of dystrophin, for both the aging population and cancer patients. Keith then talks about research at the University of California, San Diego, that has shown the beneficial effects epicatechin, a flavanol in dark chocolate. 1:00:37: Ken mentions that some athletes are using Transdermal Epicatechin, and asks about the efficacy of such practice. 1:01:54: Interview ends.

More than 90 Americans a day are dying from opioid abuse. Today’s guest, Dr. Christopher McCurdy, is at the forefront of research designed to help the U.S. deal with this drug overdose crisis. Chris is a medicinal chemist and behavioral pharmacologist at the University of Florida who is internationally known as an expert on kratom, a botanical mixture that has been shown to help people struggling with addiction. He recently became president of the American Association of Pharmaceutical Scientists, and has spent his career focusing on the design, synthesis and development of drugs to treat pain and drug abuse. Chris earned his bachelor of science degree in pharmacy from Ohio Northern University, and a Ph.D. in medicinal chemistry from the University of Georgia College of Pharmacy in 1998. He did his postdoctoral work at the University of Minnesota where he focused on opiate chemistry in relation to drug abuse and drug addiction. He joined the faculty at the University of Mississippi in 2001 where much of his research was successful in discovering unique and selective tools for sigma receptors, NPFF receptors and opioid receptors. Dr. McCurdy accepted a post as a professor of medicinal chemistry at Florida in 2017 and became the director of the university’s Translational Drug Development Core.  Links:  Christopher McCurdy UF faculty page: http://pharmacy.ufl.edu/faculty/christopher-mccurdy/ American Association of Pharmaceutical Scientists: https://www.aaps.org/home Translational Drug Development Core: https://www.ctsi.ufl.edu/research/laboratory-services/translational-drug-development-core/  Suspected Adulteration of Commercial Kratom Products with Hydroxymitragyine: https://www.ncbi.nlm.nih.gov/pubmed/27752985 Self-treatment of Opioid Withdrawal Using Kratom: https://www.ncbi.nlm.nih.gov/pubmed/18482427 Herbal Medicines for the Management of Opioid Addiction: https://www.ncbi.nlm.nih.gov/pubmed/22133323 Show notes:  2:58: Ken opens by asking Chris if he ever dreamed of becoming a professional athlete as a result of growing up in Pittsburg during the hay-day of the Stealers and the Pirates. 3:28: Dawn mentions that Chris’s father was a pharmacist, and his mother, a science teacher. She further mentions that in addition to being interested in sports, that Chris also was interested in science, and she asks what role his parents played in that. 4:45: Dawn mentions that Chris moved to a suburb of Youngstown Ohio just as he was starting high school. Chris talks about playing basketball, being part of a competitive swim team, and his reputation as a fairly straight-laced kid. 5:27: Ken mentions that Chris headed to Ohio Northern University after he graduated from high-school and initially pursued a double major in pharmacy and music. Ken asks what prompted that particular combination. 6:39: Ken talks about how at Ohio Northern, Chris’s first real mentor in science noted his talent for research, and suggested that Chris should head to the University of Georgia for the summer to get acquainted with research. Chris talks about how that eventually led to him attend Georgia for his doctorate. 10:39: Ken asks Chris to talk about his doctoral research into Native American Tobacco. 13:28: Dawn comments on how there weren’t too many post-doc opportunities available at the time he finished his studies at Georgia, but that she understands there is an apparent pattern in his life of being at the right place at the right time. She asks if it was this pattern that lead him to the University of Minnesota. 17:05: Dawn inquires as to what got Chris interested in working on the natural product called Salvinorin A (Magic Mint), and what became of that research. 20:40: Dawn mentions that because of his work on salvia divinorum, Chris was invited by the National Institute of Drug Abuse to give a talk in 2004, which is where he first learned about kratom. 23:08: As context, Ken asks if Chris could expound upon kratom’s history, the different types of kratom, and the varying effects they have on users. 32:10: Ken brings up the debate surrounding whether kratom is properly construed as an opioid. Chris goes on to talk about the differences between kratom and classic opioids. 37:33: Following up on the previous question, Ken mentions that the distinction between opioid and opiate is quite important, given that when people talk of opioids they are generally thinking of opiates specifically. Given that respiratory depression is a major issue for those on opiates, Ken asks how many lives could be saved by moving people off opiates. 40:32: Shifting the conversation, Ken asks about the use of kratom among athletes. 43:10: Ken, following up on the last question, mentions that the primary use of kratom among athletes is not for performance enhancement, but rather recovery, and coping with the pain.  One frequently hears of kratom use among athletes, especially those engaged in sports such as wrestling, mix martial arts, bodybuilding, and football to help manage the pain associated with their sport-related injuries. 47:08: Ken comments on the importance of Chris’s endeavor to perform clinical trials with kratom, and asks about the resistance he has faced in doing trials. 50:17: Dawn asks if there are any documented side effects of chronic use of kratom, and if there is the potential to overdose. 53:49: Dawn, shifting gears, mentions that while at the University of Mississippi he met Bonnie Avery, an analytical chemist, and that he began to collaborate with her. Dawn goes on to mention that Bonnie became known as the bearer of bad news, asking how she ended up with that reputation, and also how Chris ended up marrying Bonnie. 57:10: Dawn says that in 2013 the Florida Legislature announced that it was going to create a preeminence program that would provide state universities millions of dollars to attract top level faculty members and scientists. She mentions that because of this program Chris was approached, and that he and Bonnie eventually joined the Florida faculty. Dawn asks how that all came about. 59:39: Dawn asks Chris about a mentor who once advised him, “Always focus on the science, and be true to the science.” Dawn asks Chris if that is advice he, too, shares with people. 1:01:55: Interview ends.

Why is it that modern marine concrete structures crumble and corrode within decades, but 2,000-year-old Roman piers and breakwaters endure to this day? Episode 60 of STEM-Talk features Dr. Marie Jackson, a scientist who has spent the past two decades figuring out the answer to that and other questions about the durability of ancient Roman mortars and concretes. Marie is a research associate professor in the department of geology and geophysics at the University of Utah. She is known for her investigations in pyroclastic volcanism, mineralogy, materials science, and archaeological science that are breaking new ground in understanding the durability and specialty properties in ancient Roman mortars and concretes. She is particularly focused on deciphering Roman methods and materials in the hope of producing innovative, environmentally friendly cementitious masonry products and nuclear waste storage materials that would benefit the modern world. She was the lead principal investigator of a drilling project in the summer of 2017 on the Surtsey Volcano, which is on a small isolated island off the coast of Iceland. The volcano is growing the same mineral cements as Roman marine cement and the drilling project is helping provide extraordinary insights into the materials and processes the Romans used. She is particularly focused on deciphering Roman methods and materials in the hope of producing innovative, environmentally friendly cementitious masonry products and nuclear waste storage materials that would benefit the modern world. She was the lead principle investigator of a drilling project in the summer of 2017 on the Surtsey Volcano, which is on a small isolated island off the coast of Iceland. The volcano is growing the same mineral cements as Roman marine cement and the drilling project is helping provide extraordinary insights into the materials and processes the Romans used. After receiving her bachelor of science in earth sciences from the University of California Santa Cruz, Marie traveled overseas and received a doctorate from the Universite de Nantes in France. She returned stateside and received a doctor of philosophy from John Hopkins University as well as a Ph.D. in earth and planetary sciences. Marie then went to work as a research geoscientist for the U.S. Geological Survey. After taking time off to raise a family, Marie joined the department of civil and environmental engineering at the University of California, Berkeley, as a project scientist. She stepped into her current position at the University of Utah in 2016. Links: Mechanical resilience and cementitious processes in Imperial Roman architectural mortar: https://www.researchgate.net/publication/270161645_Mechanical_resilience_and_cementitious_processes_in_Imperial_Roman_architectural_mortar Marie Jackson ResearchGate profile: https://www.researchgate.net/profile/Marie_Jackson Surtsey blogspace: https://surtsey50years.utah.edu  Show notes:  4:06: Dawn begins interview by mentioning Marie’s love of the outdoors as a child and asks her to talk about those days. 4:38: Dawn asks if Marie’s father, who was a geologist, contributed to her love of the outdoors. 5:11: Dawn asks what topics Marie was interested in while in high school. 5:44: Dawn mentions that when Marie went to college, she never envisioned herself as a scientist, but this changed in her junior year, when her interest in earth sciences took root. Dawn asks Marie to elaborate on how that happened. 6:27: Ken asks Marie what role, if any, her family’s ranch played in motivating her interest in geology. 7:22: Dawn mentions that after college Marie worked for a mining company for a few years, which enabled her to save enough money to travel to France, where she worked on a doctorate. She asks if this is how Marie ended up in northern Corsica, in the Italian Alps. 9:39: Ken asks about her transition back to the United States, where she attended John Hopkins University after spending 3 years in France. 10:23: Ken mentions Marie’s reputation at John Hopkins for being a “desert rat” in Utah’s Henry mountains. He asks her to elaborate on her experiences in that area. 12:06: Dawn comments on how after Marie got her PhD in 1987, she went to work for the U.S. Geological Survey, and that she ended up doing a structural study of the seismically active Kaoiki fault zone on the southeast flank of the Mauna Loa Volcano in Hawaii. Dawn asks Marie to talk about that. 13:44: Dawn comments on how Marie didn’t know much about Rome until she spent a year there in 1995. Marie talks about her experience. 14:17: Ken mentions that Marie’s priority for many years was to raise her children, but Ken asks what else she did in those days. 15:05: Dawn comments on how during this period, Marie was writing papers and working with scientists who were nearing retirement.  Dawn asks what that was like. 17:55: Dawn asks about the work Marie did after she started, in 2011, working at UC Berkley’s Department of Civil and Environmental Engineering as a project scientist. 19:55: Ken mentions that after a couple of years at Berkley, Marie accepted a position at the University of Utah. He comments on how that must have been an interesting transition to come full circle back to Utah. 20:44: Dawn asks for Marie to explain exactly how the Romans made concrete, and what made it so unique. 22:11: Ken mentions that while modern maritime concrete structures typically degrade significantly within a matter of decades, the Romans built piers and breakwaters 2,000 years ago that endure to this very day. He inquires as to what prevents Roman maritime concrete from degrading. 26:42: Ken comments on how the Romans are often said to be very deliberative people. He asks how much of the invention of their concrete does Marie think was deliberate, and how much a happy accident. 28:51: Ken asks about a comment that Pliny the Elder made in the first century about how the best maritime concrete was made from volcanic ash found in the regions along the Gulf of Naples. Ken asks Marie what is so particularly special about the ash at that particular region. 31:24: Ken mentions the Romacons project, and the book that came out of it, “Building for Eternity,” which was published in 2014. Marie is one of the authors, and the book explains how the Romans built these lasting structures in the sea. He asks if Marie could elaborate on the story the book tells. 35:14: Dawn asks Marie what the cementing characteristics are that have made Roman concrete so unique. 37:23: Ken mentions the demonstrated durability and longevity of Roman maritime concrete. He asks if lessons learned from the Romans could be of relevance to engineers currently working on devising containment for long term storage of hazardous waste substances. 41:11: Marie talks about her current project as the lead principle investigator on the Surtsey Volcano. 44:48: Dawn asks how Marie is disseminating the knowledge and information about the work that she and her team are doing at Surtsey. 46:20: Dawn asks Marie what life and career advice she would give to an up and coming scientist. 47:11: Ken inquires as to what Marie enjoys doing in her time away from research. 48:31: Interview ends.

Nearly five million people in the United States have Alzheimer’s disease. In 30 years, that number is estimated to be 16 million In today’s episode, Ken and Dawn interview Dr. Stephen Cunnane, a Canadian physiologist whose extensive research into Alzheimer’s disease is showing how ketones can be used as part of a prevention approach that helps delay or slow down the onset of Alzheimer’s. Cunnane is a metabolic physiologist at the University of Sherbrooke in Sherbrooke, Quebec. He is the author of five books, including” Survival of the Fattest: The Key to Human Brain Evolution,” which was published in 2005, and “Human Brain Evolution: Influence of Fresh and Coastal Food Resources,” which was published in 2010. He earned his Ph.D. in Physiology at McGill University in 1980 and did post-doctoral research on nutrition and brain development in Aberdeen, Scotland, London, and Nova Scotia. From 1986 to 2003, he was a faculty member in the Department of Nutritional Sciences at the University of Toronto where his research focused on the role of omega-3 fatty acids in brain development and human health. He also did research on the relation between ketones and a high-fat ketogenic diet on brain development. In 2003, Dr. Cunnane was awarded a senior Canada Research Chair at the Research Center on Aging and became a full professor at the University of Sherbrooke. He has published more than 280 peer-reviewed research papers and was elected to the French National Academy of Medicine in 2009. Links: Lower Brain 18F-Fluorodeoxyglucose Uptake: Castellano et al AD dPET J Alz Dis 2015 Brain glucose and acetoacetate metabolism: Nugent et al dPET YE Neurobiol Aging 2014 Energetic and nutritional constraints on infant brain development: Cunnane & Crawford J Human Evol 2014 Inverse relationship between brain glucose and ketone metabolism in adults: Courchesne-Loyer et al PET KD JCBFM 2016 A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults: Croteau et al. AD MCI CMR Exper Gerontol 2017 A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer’s Disease: Castellano et al. exercise ketones JAD 2017 Show notes: 3:33: Dawn mentions that Stephen was born in London but that his family emigrated to Canada when he was an infant. She asks him about growing up in a suburb of Montreal. 4:02: Ken mentions that he has been told by a reliable source that as soon as Stephen got into high school he spent a lot of time in the chemistry lab, where sometimes created mischief. 4:58: Dawn asks if it is true that Stephen nearly flunked out of college when he first started. 5:16: Dawn comments that Stephen got his PHD in physiology at McGill University which is when his interest in science really caught on and asks how that came about. 5:55: Stephen talks about communicating with Desmond Morris while Stephen was working on his post-doc. 8:03: Dawn asks about Stephen’s post-doctoral research, for which he traveled to Aberdeen London and Nova Scotia; as well as what prompted his interest in nutrition in the brain. 9:01: Dawn mentions that in 1986 Stephen became a faculty member in the department of nutritional sciences at the University of Toronto. She asks how he ended up teaching nutrition when he didn’t have a degree in nutrition. 10:33: Stephen talks about accepting a senior Canada Research Chair at the Research Center of Aging and a full professorship at the University of Sherbrooke. 11:57: Ken talks about Stephen’s interest in human evolution how it eventually led him to research the nutritional importance of shore-based foods and omega-3 fatty acid in particular in the development of human’s brains. He asks Stephen to talk about his work leading up to the hypothesis that humans evolved near the water. 16:32: Dawn asks which of the various forms and sources of omega-3 are optimal for overall wellness and brain health, and what are the differences between them. 18:50: Dawn asks Stephen if there was any pushback against his research into the importance of ketones and fat in the brain development of infants? Dawn points out that Stephen was working on this during the middle of the low-fat craze in the U.S. and Canada. 20:33: Dawn mentions that there is evidence that intermittent fasting improves cognition, and asks if there is any evolutionary basis for that? 21:49: Dawn asks if it was Stephen’s research into the metabolism of omega-3 fatty acids and the importance of ketones that lead him to write his book Survival of the Fattest? 23:04: Dawn notes that it seems as if ketones are at the core of Stephen’s way of thinking about infant brain development. She asks him to elaborate on this. 24:15: Dawn asks Stephen to talk about what it’s going to take to transition to the therapeutic use of ketones. 26:06: Ken mentions how Stephen has noted the importance of ketosis in postnatal life for a number of reasons, including brain development and survival and early breast milk availability. Ken asks about the effect of women consuming a ketogenic diet while breastfeeding children, and if this inadvertently lowers ketone levels in the infant due to lower medium chain triglyceride (MCT) levels in the breast milk, a phenomenon found in rodents fed a ketogenic diet during lactation. 28:36: Dawn comments how Stephen has said that certain brain-selective nutrients — such as DHA, iodine, iron, selenium, zinc and copper — would be best supplied by a shore-based diet. She asks which shores humans would have evolved close to and which types of food made up this diet during human evolution? 32:29: Dawn mentions that at Sherbrooke, Stephen’s research has been focused on the use of brain imaging techniques to study changing brain fuel metabolism and cognitive function during aging. She asks if he can give an overview of what he is finding. 34:08: Dawn comments on the increasing interest in exogenous ketones for treatment of neurological disease. She further mentions that these ketone esters can elevate Beta-hydroxybutyrate (BHB) levels far beyond what is normally attained during the ketogenic diet. She asks Stephen for his thoughts on the initiation of ketosis through MCTs versus exogenous ketones (salts or esters) versus carbohydrate restriction versus fasting. She asks about mechanistic differences between each of these methods of initiating ketosis. 35:39: Ken mentions that Stephen’s tracer work has used 11c acetoacetate in the setting of endogenous ketones and neurological disease. He asks if there are any key differences in brain ketone metabolism between endogenous and exogenesis ketosis after mentioning how BHB and acetoacetate appear in a relatively predictable 1:1 ratio when ketosis is induced through diet. 37:28: Ken mentions that it has been noted that ketones are 10% more efficient than glucose as a brain fuel. He asks Stephen about his understanding of cerebral fuel selection given ample availability of both glucose and ketones. 38:25: Dawn asks if there are areas of the brain that are particularly high users of ketone bodies, and if so, could that have any link to some of the functional or behavioral changes, such as mood, that are seen in some cases of animals or people adhering to a ketogenic diet. 39:16: Dawn asks Stephen to talk about his research into how and why omega-3 fatty acid homeostasis changes during aging. 40:21: Dawn asks for Stephen’s opinion on what are the primary challenges that our brains face as we age. 41:12: Dawn mentions how that Stephen is currently focused on Alzheimer’s research and ketones. She asks for an overview of his research that’s looking into how ketones can be used to the advantage of a person suffering from Alzheimer’s disease. 43:21: Dawn comments on how we know that APOE4 carriers have an increased risk of development of late onset familial Alzheimer’s disease. She asks if there is a link between the genotype and a change in brain metabolism. 44:42: Ken asks if substrate utilization differs between healthy subjects and those with neurological conditions, such as mild cognitive impairment or Alzheimer’s disease. 45:18: Dawn asks Stephen what other metabolic interventions he thinks have promise for a neurodegenerative disease. 46:01: Dawn mentions that exercise helps to get more ketones into the brain. She inquires as to how much exercise is needed to do this effectively. 46:49: Dawn asks Stephen to elaborate on his recommendation that older people who might not be able to exercise effectively should consider consuming a ketone drink made from MCTs that people can make in their kitchen. 48:31: Ken comments how he envisions it not being too long before studies can be done with powerful ketone ester drinks, and that exogenous ketones will become more readily available and more potent, giving people more effective options to elevate their level of circulating ketones. 50:09: Dawn asks Stephen if chronically high systemic inflammations contribute to neuroinflammation and cognitive decline. She also asks if targeting systemic inflammation with nutritional ketosis would be an acceptable strategy to enhance and also preserve cognitive function and brain longevity. 51:15: Dawn mentions that we know ketones increase brain blood flow and metabolism. She goes on to ask if Stephen thinks that some of the beneficial effects might be working through the newly discovered brain lymphatic system or glymphatic system. 51:41: Dawn points out there are about five million people with Alzheimer’s disease in the U.S., and that the number of Americans with AD is estimated to swell to 16 million in the next 30 years. She asks if Stephen thinks this dramatic increase in the prevalence of Alzheimer’s is related to the Western diet which has created an epidemic of type-2 diabetes and other chronic diseases. 52:42: Ken mentions that a number of recent papers show dramatic improvements in both health span and life span of rodents that are fed a ketogenic diet. While humans are not rats, he asks Stephen for his thoughts on the effects of prolonged ketosis as a promoter of human healthspan and perhaps even longevity. 53:51: Dawn concludes the interview by asking Stephen’s about his interests outside of work.

Today’s episode features one of the nation’s leading physicians and researchers who has spent years studying and treating traumatic brain injuries. Dr. Flora Hammond is a professor and chair of the Department of Physical Medicine and Rehabilitation at Indiana University School of Medicine. She also is the Chief of Medical Affairs and Medical Director at the Rehabilitation Hospital of Indiana. She has been a project director for the Traumatic Brain Injury Model System since 1998. Shortly before we conducted this interview with Dr. Hammond, she and a team of physicians and scientists at Indiana University received a $2.1 million grant to continue research into people who suffer traumatic brain injuries and how these injuries affect the lives of patients as well as their families. Dr. Hammond is a Pensacola, Florida, native who graduated from the Tulane University School of Medicine in 1990 and completed her residency in Physical Medicine and Rehabilitation at the Baylor College of Medicine in Houston. She also completed a brain injury medicine fellowship at Wayne State University School of Medicine in Detroit. Her research in the area of brain injury includes studying the prediction of outcome, aging with brain injury, causes of and treatments for irritability, and quality of relationships. In 2016 she received the Robert L. Moody Prize, which is the nation’s highest honor reserved for individuals who had made exceptional and sustained contributions to the lives of individuals with brain injuries. Prior to the 2016 Robert L. Moody Prize, Dr. Hammond received local and national awards for her teaching, clinical care and research, including the 2001 Association of Academic Physiatrists Young Academician Award, the 2011 Brain Injury Association of America William Caveness Award, and the 2013 Baylor College of Medicine Distinguished Alumnus Award. In 2011, 2012, and 2013, Dr. Hammond led the Galveston Brain Injury Conferences which focused on changing the view of brain injury as an incident with limited short-term treatment to a chronic condition that must be proactively managed over the course of life. She co-chairs the American Congress of Rehabilitation Medicine Chronic Brain Injury Task Force, and serves on Journal of Head Trauma Rehabilitation editorial board. She has authored more than 140 peer-reviewed publications. Links: Flora Hamond faculty profile: https://medicine.iu.edu/faculty/20302/hammond-flora/ “Potential Impact of Amantadine on Aggression” study https://www.ncbi.nlm.nih.gov/pubmed/28891908 Show notes: 4:08: Interview begins. 4:38: Dawn says it’s her understanding that Flora dreamed of becoming a physician ever since middle school. Dawn asks what inspired her at such an early age to become a doctor. 5:02: Flora talks about also wanting to become a teacher, but worried that she would have to give up teaching to become a doctor. 5:40: Continuing with Flora’s history, Dawn mentions that after high school Flora traveled to New Orleans to attend Tulane University. Dawn asks if it’s true that Flora’s grandmother was her landlord while she was in college and med school. 6:20: Ken mentions that Flora’s mother was a dietician and that her father was a pathologist. He asks Flora what specifically inspired her to specialize in brain injury rehabilitation and research. 8:36: Dawn comments on how before Flora accepted a positon at Indiana, she was in the Carolinas, and asks about her work there. 9:30: Dawn asks how Flora ended up at the Indiana University School of Medicine. 10:23: Ken mentions that Flora’s lecture at IHMC attracted a lot of interest and a full-house. He follows up by asking Flora what she thinks is driving the interest in brain injuries. 11:34: Dawn talks about how Flora and a team of physicians and scientists at Indiana have spent years studying and treating TBI (Traumatic Brain Injury) and the effects of TBI on the lives of patients and their families. She goes on to mention that Indiana recently was awarded a $2.1 million grant to continue those studies for the next five years. Dawns asks Flora to talk about the scope of the work she will be doing as a result of the grant. 12:57: Ken mentions that Flora has pushed to have a national approach to the treatment of TBI, where patients and physicians continuously track the injury and continue treatments. He asks her to expand on her thoughts on such a program and how more people and organizations can start working toward an integrated approach. 13:48: Dawn asks for Flora to explain the different types of brain injury, and to clarify that TBI is not merely one singular disease or type of injury process.  Flora goes on to explain the difference between mild, moderate and severe injuries, and then describes how the treatments differ. 14:50: Dawn asks Flora how she diagnoses the severity of TBI, and if there are any biomarkers that are currently in use. 16:01: Dawn asks what common issues patients struggle with after a traumatic brain injury. 17:08: Dawn proposes the hypothetical scenario of a patient coming into Flora’s rehabilitation clinic, and asks Flora to walk us through an example of how they would treat that person and what program they would go through. 19:21: Ken mentions that there are a number of TBI centers that focus on integrative medicine, and rather than just treating the brain injury they are now treating the patient as a whole human being. He talks about optimizing sleep, proper nutrition, and ways to manage aggression and anxiety in addition to specific treatment of the brain. He asks Flora how much does it seem that physicians are currently integrating these approaches into TBI treatment around the country. 20:17: Dawn asks what we know about the triggers of irritability and aggression in TBI patients, and if there is a biochemical component to these triggers or if it is something else. 22:21: Dawn inquires as to the different ways that Flora uses to track a patient’s condition on the cognitive or emotional level. 22:45: Flora talks about research on aging after TBI, and that interestingly enough, it’s not always about worsened outcomes. Some people actually get better over time, while others stay the same or their condition even worsens over time. Dawn asks if there are ways to differentiate who will improve and who will worsen with time. 23:50: Ken comments on how in the past it was thought that brain plasticity, and thereby recovery, was more plausible for a child with TBI, but that recovery would plateau at some point. He points out, however, that much of Flora’s work has shown that recovery can occur in older individuals and they can continue to improve long after the initial injury. He asks Flora if she could talk about that work. 24:44: Dawn asks if there is a difference in treatment for a child with TBI compared to an adult with a similar injury. 25:17: Ken mentions that ApoE 4/4, and even 3/4 status, has been shown to be a genotype that is associated with worsened patient outcomes after TBI, and that there are other genetic variables beyond ApoE that are relevant. He asks, in regards to the era of precision medicine, are we looking at these genetic variables with respect to a personalized patient treatment program? 26:21: Ken asks if we are able to accurately predict outcomes in the early hours and days following the injury. 27:00: Dawn asks if a severe brain injury typically implies a poorer outcome. 27:36: Mentioning that she has several people close to her with various types of TBI, Dawn talks about how she loves the idea of a participatory research system that Flora has proposed and implemented. Dawn asks Flora to expand on this approach to TBI research. 28:31: Ken talks about how Flora has focused a lot of her research on non-pharmacological interventions for TBI. He asks for some examples of approaches that she has studied, and if those approaches are being harnessed by the general TBI treatment community. 29:33: Ken mentions that Flora recently published a study on the promising ability of the drug Amantadine to curb aggression in TBI patients. He asks if she could elaborate on that. 33:27: Dawn comments on how in most treatment modalities for brain injury, the focus is on the acute phase. She asks how can treatment be extended after the initial management, and what else does Flora think long-term treatments for TBI patients should include. 34:13: Dawn asks if it is true that all of the recovery from a brain injury happens within the first year. 35:08: Dawn asks if medication in the early recovery phase has a downside in the long term. 36:01: Ken mentions that a number of therapies for TBI that showed great promise in animal studies, failed to yield the hoped-for results in human trials. He asks what are the current barriers to developing new acute therapies that reduce morbidity and mortality in TBI patients are. 37:09: Ken comments on how TBI is an injury to the brain, but it also affects a variety of other systems and pathways in the body. He mentions that the Hypothalamic Pituitary Adrenal access can often be impacted in TBI patients. He asks for a brief explanation of the HP access and how damage to it can affect the patient. 38:38: Ken asks if there would ever be a case where a person with HPA access as their dysfunction could be misdiagnosed with TBI and vice versa? 39:24: Dawn mentions that it seems as though the HPA axis  has been widely ignored, comparatively speaking, to other metrics in TBI patients. She asks if we are starting to include its assessment and status in patients, as far as tracking is concerned. 39:52: Dawn comments on how Flora has coined the term CBI (Chronic Brain Injury). Dawn asks if CBI has been incorporated into a public health and societal approach, in addition to traditional medicine. 40:37: Ken asks Flora to elaborate on how she would scope and define CBI as opposed to TBI. 41:17: Dawn asks for Flora to talk about how brain injury rehab has evolved over her career. 42:21: Dawn congratulates Flora on receiving the Robert L. Moody Prize last year, which is the nation’s highest honor for individuals who have made exceptional and sustained contributions to the lives of people with brain injuries. She follows up by asking for some background on the award itself. 42:48: Dawn asks where Flora sees the field of TBI research and rehabilitation heading in the next 10 years. 43:48: Dawn closes by asking Flora how she likes to spend her free time.

Today’s interview features Dr. Lauren Jackson, a nationally known expert in the field of tumor and normal-tissue radiobiology. She is especially recognized for her expertise in medical countermeasure development for acute radiation sickness and delayed effects of acute radiation exposure. Lauren is the deputy director of the Division of Translational Radiation Sciences within the Department of Radiation Oncology at the University of Maryland School of Medicine. Lauren, who also goes by Isabel, received her bachelors in science in microbiology from North Carolina State University in 2006, and her PhD in pathology from Duke University in 2012. She currently is a principal or collaborating investigator on a number of industry and federally sponsored contracts and research grants. She has published extensively on the characterization and refinement of animal models of radiation-induced normal tissue injury that recapitulate the response in humans. Models developed in Lauren’s laboratory have gone on to receive FDA concurrence as appropriate for use in medical countermeasure screens. Lauren is a senior associate editor for Advances in Radiation Oncology, a journal of the American Society of Therapeutic Radiation Oncology, and serves as an ad hoc reviewer for several peer-reviewed journals. She also is the author of several book chapters on normal tissue tolerance to radiation, mechanisms of injury, and potential therapeutic interventions. Links: Jackson’s University of Maryland web page: http://www.medschool.umaryland.edu/profiles/Jackson-Isabel/ Radiation Emergency Medical Management website: https://www.remm.nlm.gov Centers for Disease Control website: https://www.emergency.cdc.gov/radiation/index.asp BARDA website: https://www.phe.gov/about/BARDA/Pages/default.aspx NIAID website: https://www.niaid.nih.gov Show notes: 5:06: Dawn begins interview by asking Lauren about her childhood and if it’s true that she was one of those children who was always asking questions? 5:39: Lauren talks about how she was more interested in history and the humanities in high school and wanted nothing to do with science. 5:59: Dawn asks Lauren about her decision to attend the University of Georgia to major in journalism and political science. 6:28: Ken comments on how even though Lauren was just 18 at the time, she was one of two students picked to represent the University of Georgia at the Center for the Presidency in Washington, D.C. Lauren then talks about how thanks to that experience, she decided journalism and political science weren’t the right majors for her. 7:38: Dawn points out that when Lauren first went to college, she took the minimum number of science classes.  Lauren goes on to talk about how after spending time in D.C., she ended up applying to North Carolina State University and switching her major to microbiology. 8:52: While at N.C. State, Lauren worked for Dr. Hosni Hassan, an expert on Oxidative Stress. Dawn asks Lauren about the focus of her research with Dr. Hassan. 9:58 Dawn talks about how when Lauren was an undergrad at N.C. State, she became interested in tumors and cancer treatment, and found a professor down the road at Duke University who was doing interesting work in that area. Dawn asks Lauren if that’s why she ended up going to Duke for her doctorate. 10:52 Dawn asks Lauren to elaborate on how her background in journalism and political science connected her towards the path of radiation countermeasure research.  11:42 Dawn points out that as a graduate student at Duke, Lauren took part in projects that looked at radiation injury. Dawn asks Lauren to give an overview of what sort of work was involved in the projects.  12:46 Ken asks Lauren to explain the difference between clinical radiation exposure and radiation that someone would experience as a consequence of a nuclear attack. 13:59: Ken shifts the conversation to human space flight, asking Lauren to discuss the radiation astronauts will experience outside the protection of the Earth’s magnetosphere, such as galactic cosmic radiation and solar particle events. He also asks how they relate to the other previously mentioned clinical- and weapons-based radiation. 14:52: Ken asks Lauren to describe what the lifetime limits are for radiation exposure, how they are produced, and what is the biggest source of radiation exposure for the average person. 16:06: Dawn asks if it’s possible to translate the findings in clinical radiation to these other types of radiation exposures, such as nuclear weapons and space radiation. 16:40: Dawn asks if clinical radiation research is playing a role in the work that’s being done in space research as well as research into the effects of nuclear-weapons attack. 17:27: Ken asks Lauren to explain how radiation doses are defined. 18:28: Ken mentions that Lauren’s work has focused on both the acute and chronic effects of radiation exposure, then asks her to give an overview on how the body would respond at the cellular and physiological levels to an acute exposure. 19:56: Dawn mentions how proximity to the event, in the event of a nuclear attack, would be a variable factor as to the level of exposure, then asking what else determines the degree of an acute response. 22:35: Dawn asks if the impact of radiation exposure is different based on different systems in the body, further asking which systems are more or less susceptible and what the different responses are. 24:06: Dawn mentions how Lauren has focused a large part of her research on the effects of radiation exposure to the pulmonary system, then asking her to talk about those chronic and lifetime affects following initial exposure. 25:38: Ken remarks how oxidative stress is a major focus on Lauren’s research, and follows up by asking about the impact of oxidative stress on the tissue, surrounding tissue, and its role in the overall injury response. 26:54: Ken remarks on the evidence that shows that animals fed a diet high in blueberries have some degree of resistance to the inflammatory response due to the blueberry’s antioxidant activity. He asks if antioxidants, more broadly, could play a role in the prevention of radiation injury. 27:46: Dawn asks about genetic susceptibility to radiation injury, and if we know of any individuals who are more or less susceptible to injury based on their genetic makeup. 28:48: Ken wonders if the genetic screening for radiation tolerance were developed adequately, that perhaps it could have an application in the selection process for long-duration missions into deep space. 29:25: Ken inquiries about the counterintuitive fact that smokers have a reduced incidence of radiation-induced lung cancer. 30:07: Dawn asks if gender or age play a role in a person’s susceptibility to radiation injury. 31:13: Dawn mentions how we know that epigenetic modifications (changes with respect to how a gene is expressed) can occur in response to a wide variety of different stressors or environmental influences. She then asks if we are seeing modifications that occur as a result of radiation exposure at the epigenetic level. 31:47: Dawn mentions that Randy Gerald was at Duke at the same time that she and Lauren were at Duke, and that he was the founder of epigenetic modifications. 32:15: Ken asks that in regards to a point-of-care test that could identify individuals who have been exposed to radiation and injured, what are the potential markers that Lauren would look for. 34:01: Dawn asks if markers of tissue injury, such as lung-radiation injury, are found in the blood. 35:44 Ken mentions the importance of timing from the point of injury as being critical with most biomarkers. He then asks that given the temporal nature of radiation injury, is there a time effect on biomarkers of radiation injury. 36:37: Ken asks about the effects of radon. 37:30: Ken notes that some areas are inherently much higher in radon levels than others, such as New England, and parts of Florida. He asks if there is a level that Lauren would consider safe for basements. 38:42: Dawn asks about the current position Lauren holds at the University of Maryland School of Medicine as the Deputy Director of the Division of Translational Research Sciences, and the Department of Radiation Oncology, and her research team that she has there. 40:32: Dawn asks about the different categories of potential countermeasures for radiation injury that Lauren has been looking at. 41:28: Dawn mentions how Lauren also works alongside the FDA, where she serves as a subject-matter expert for the review committees. She asks Lauren to describe her work with the FDA and in particular the FDA animal rule and the role that plays in countermeasure approval for humans. 44:03: Lauren explains the role that the NIAID (National Institute for Allergy and Infectious Disease) plays in countermeasure development. 45:56: Ken asks if countermeasures that we might develop to limit the damage from a nuclear attack might potentially be used for applications such as clinical radiation or space radiation exposure. 47:12: Dawn asks about a countermeasure drug called Bio300 that Lauren worked on with a company called Humanetics Corporation, asking where it stands with respect to research and potential clinical applications in humans. 48:37: Dawn asks Lauren to talk about the approval process and the specifics of Neupogen and Neulasta, (the first two drugs ever approved as potential countermeasures for acute radiation syndrome) that were approved on the basis of data generated at Lauren’s laboratory. 49:58: Ken notes that Neupogen has demonstrated improved survival in people exposed to lethal radiation doses on Earth, then asks if Neupogen, Neulasta, or some other bone-marrow active medical countermeasures have applications in human space flight. 50:54: Dawn asks if there is a one-size-fits-all drug to target all the physiological systems in response to radiation exposure, or if a patient would need to take an array of countermeasures to cover each of the different systems. 52:22: Dawn notes that after Fukushima, potassium iodine pills were flying off the shelves, and asks if that is a viable option for protection against acute radiation syndrome. 53:32: Ken asks if there are any prophylactic treatments approved or in development for radiation exposure. 54:46: Ken asks Lauren to talk a little more about BARDA (Biomedical Advanced Research and Development Authority) and the role it plays in radiation injury research and countermeasure development. 56:44: Dawn notes that Lauren has served as the program director for the BARDA Radiological and Nuclear Model Development Program, asking her to talk about that position and what that work entails. 57:25: Lauren talks about how it seemed that no one was interested in radiation after the Cold War, but that recent interest in radiation research has grown significantly. 59:48: Dawn mentions that four or five years ago you couldn’t get any companies interested in looking at ways to improve survival in case of a nuclear attack, but that in just the last two weeks of November that Lauren has had 22 companies reach out to her. 1:01:48: Dawn asks what the current threats of nuclear or radiological terrorism or nuclear attack are. 1:02:18: Ken asks how much protection to radiation exposure, arising from a weapon’s detonation, does a basement offer. 1:03:05: Ken remarks how, in regards to basements, those that do not have windows would be preferable in the context of protecting against radiation exposure. 1:04:13: Ken asks if any of the countermeasures developed thus far could be effective against space radiation, and thereby offer NASA an ability to leverage the BARDA investment. 1:05:26: Ken remarks how he is glad to hear that the federal agencies are wisely leveraging each other’s investments, rather than independently pursuing them. 1:06:31: Ken talks about long-duration missions in deep space and the possibility that astronauts might experience serious cognitive deficits caused by radiation exposure. He also points out the need for a countermeasure against cognitive decline as a result of radiation is not yet met here on Earth, citing that workers who cleaned up the Chernobyl nuclear disaster experienced serious cognitive decline close to ten years after the incident. 1:08:22: Ken asks if potential neurocognitive medical countermeasures exist today or if they may be available in the near future, and would a single agent be effective for both terrestrial exposures and the galactic cosmic radiation found in space. 1:09:18: Dawn wraps up the interview by asking Lauren if she is an N.C. State fan or a Duke fan when it comes to basketball.